ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ELGX Endologix Inc

0.22
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Endologix Inc NASDAQ:ELGX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.22 0.2344 0.24 0 01:00:00

Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017

10/10/2017 9:01pm

Business Wire


Endologix (NASDAQ:ELGX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Endologix Charts.

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call, dial 877-407-9716 (domestic) or 201-493-6779 (international).

This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Tuesday, November 7, 2017, until 11:59 p.m. ET on Tuesday, November 14, 2017. To hear this recording, dial 844-512-2921 (domestic) or 412-317-6671 (international) and enter the passcode 13672121.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.

Investors:Endologix, Inc.Vaseem Mahboob, CFO949-595-7200

1 Year Endologix Chart

1 Year Endologix Chart

1 Month Endologix Chart

1 Month Endologix Chart

Your Recent History

Delayed Upgrade Clock